Literature DB >> 12065886

Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells.

Mathias Z Strowski1, Michael P Dashkevicz, Rupa M Parmar, Hilary Wilkinson, Martin Kohler, James M Schaeffer, Allan D Blake.   

Abstract

Somatostatin (SRIH) regulates pituitary adrenocorticotropin (ACTH) secretion by interacting with a family of homologous G protein-coupled membrane receptors. The SRIH receptor subtypes (sst(1)-sst(5)) that control ACTH release remain unknown. Using novel, subtype-selective SRIH analogs, we have identified the SRIH receptor subtypes involved in regulating ACTH release from AtT-20 cells, a model for cell line pituitary corticotropes. Radioligand-binding studies with (125)I-SRIH-14 and (125)I-SRIH-28 showed that SRIH-14 and SRIH-28 recognized specific, high-affinity and saturable membrane-binding sites. Nonpeptidyl agonists with selectivity for the sst(2) (L-779,976; compound 2) or sst(1)/sst(5)) (L-817,818; compound 5) receptor subtypes potently displaced (125)I-SRIH-28 from AtT-20 cell membranes, while agonists selective for the sst(1) (L-779,591; compound 1), sst(3) (L-796,778; compound 3) or sst(4) (L-803,087; compound 4) subtypes were inactive. Tyr(11)-SRIH-14, compound 2 (sst(2)) or compound 5 (sst(5)) inhibited forskolin and corticotropin-releasing hormone (CRH)-induced increases in intracellular cAMP. Furthermore, the sst(2) and sst(5) agonists potently inhibited CRH-induced ACTH release from AtT-20 cells. These results provide the first evidence that sst(2) and sst(5) receptor subtypes, but not sst(1), sst(3) or sst(4), inhibit cAMP accumulation and regulate ACTH secretion in the AtT-20 cell model of the rodent corticotrope. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065886     DOI: 10.1159/000059430

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  14 in total

1.  Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.

Authors:  Davide Cervia; Dominique Fehlmann; Daniel Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-15       Impact factor: 3.000

Review 2.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 4.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

5.  Characterization of agonist-dependent somatostatin receptor subtype 2 trafficking in neuroendocrine cells.

Authors:  Walaa Alshafie; Yingzhou Edward Pan; Hans-Jürgen Kreienkamp; Thomas Stroh
Journal:  Endocrine       Date:  2020-05-07       Impact factor: 3.633

6.  Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function.

Authors:  Masaaki Yamamoto; Anat Ben-Shlomo; Hiraku Kameda; Hidenori Fukuoka; Nan Deng; Yan Ding; Shlomo Melmed
Journal:  JCI Insight       Date:  2018-10-04

7.  Medical treatment of Cushing's disease: Overview and recent findings.

Authors:  Stephanie Smooke Praw; Anthony P Heaney
Journal:  Int J Gen Med       Date:  2009-12-29

Review 8.  Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes.

Authors:  Andreas Stengel; Jean Rivier; Yvette Taché
Journal:  Peptides       Date:  2012-12-31       Impact factor: 3.750

9.  Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs.

Authors:  Davide Cervia; Caroline Nunn; Dominique Fehlmann; Daniel Langenegger; Edi Schuepbach; Daniel Hoyer
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

Review 10.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.